ARDS OTC
Aridis Pharmaceuticals, Inc.
1W: +0.0%
1M: +0.0%
3M: +0.0%
YTD: -50.0%
1Y: -92.3%
3Y: -99.9%
5Y: -100.0%
$0.00
+0.00 (+0.00%)
Overview
News
Chart
Smart Money
Financials
Income Statement
Cash Flow
Balance Sheet
Earnings
Dividends
Analysis
Technicals
Weather
Peers
ESG
Institutions
Dark Pool
Short Interest
Income Trends
Revenue
$0
+0.0% ▲
Gross Profit
$0
+0.0% ▲
Operating Income
-$30M
+31.4% ▲
Net Income
-$31M
+27.3% ▲
EPS (Diluted)
$-1.64
+52.3% ▲
EBITDA
-$30M
+33.6% ▲
Profit Margins
Year-over-Year Growth
View Full Income Statement
| Line Item | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 |
|---|---|---|---|---|---|
| Revenue | $3M | $1M | $1M | $0 | $0 |
| YoY Growth | +220.6% | -62.9% | -2.2% | -100.0% | +0.0% |
| Cost of Revenue | $0 | $0 | $0 | $0 | $0 |
| Gross Profit | $3M | $1M | $1M | $0 | $0 |
| Gross Margin | 100.0% | 100.0% | 100.0% | — | — |
| R&D Expenses | $23M | $24M | $17M | $38M | $26M |
| SG&A Expenses | $4M | $6M | $6M | $7M | $7M |
| Operating Expenses | $27M | $30M | $23M | $44M | $30M |
| Operating Income | -$24M | -$29M | -$22M | -$44M | -$30M |
| Operating Margin | -874.8% | -2846.1% | -2240.1% | — | — |
| Interest Expense | $420K | $0 | $0 | -$245K | $378K |
| Income Before Tax | -$22M | -$30M | -$22M | -$43M | -$30M |
| Tax Expense | $0 | $0 | $0 | -$912K | $378K |
| Net Income | -$22M | -$30M | -$22M | -$42M | -$31M |
| Net Margin | -801.8% | -2904.2% | -2233.3% | — | — |
| EPS (Diluted) | $-7.02 | $-3.43 | $-2.44 | $-3.44 | $-1.64 |
| EBITDA | -$24M | -$29M | -$22M | -$44M | -$30M |
| Shares Outstanding | 3M | 8M | 9M | 12M | 19M |